{
    "Trade/Device Name(s)": [
        "CONTOUR\u00ae PLUS BLUE Blood Glucose Monitoring System",
        "CONTOUR\u00ae NEXT GEN Blood Glucose Monitoring System"
    ],
    "Submitter Information": "Ascensia Diabetes Care US Inc.",
    "510(k) Number": "K241787",
    "Predicate Device Reference 510(k) Number(s)": [
        "K223293",
        "K231679"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW"
    ],
    "Summary Letter Date": "June 20, 2024",
    "Summary Letter Received Date": "June 21, 2024",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Fresh capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "CONTOUR\u00ae NEXT GEN meter",
        "CONTOUR\u00ae PLUS BLUE meter",
        "CONTOUR\u00ae Diabetes app"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemical reaction"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "System",
        "Meter",
        "App",
        "Test strip",
        "Control solution"
    ],
    "Document Summary": "FDA 510(k) summary for CONTOUR\u00ae PLUS BLUE and CONTOUR\u00ae NEXT GEN blood glucose monitoring systems with alternate Bluetooth microprocessor",
    "Indications for Use Summary": "Intended for quantitative measurement of glucose in fresh capillary whole blood from the fingertip for self-testing by individuals with diabetes at home as an aid in monitoring diabetes control; not for diagnosis, screening, or neonatal use",
    "fda_folder": "Clinical Chemistry"
}